EQS-News: Cantourage Group SE / Key word(s): Research Update Cantourage Group SE: NuWays confirms ‘Buy’ recommendation 25.10.2023 / 11:32 CET/CEST The issuer is solely responsible for the content of this announcement. Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful. The important notices at the end of this press release should be observed. Cantourage Group SE: NuWays confirms “Buy” recommendation Berlin, October 25, 2023 – In a research update published today, the research house NuWays AG, Hamburg, once again rates the shares of Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01, www.cantourage.com/en) with a “Buy” recommendation and a price target of EUR 12.50. Further information is available at https://www.cantourage.com/en/investors/analysts. About Cantourage For further information: www.cantourage.com/en This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
Press contact at Cantourage: 25.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Drug Slashes Risk of Severe Allergic Reactions to Multiple Foods
WASHINGTON — Regular courses of omalizumab (Xolair) injections increased the amount of peanut and other foods that multi-food allergic children could consume without an allergic